• 1. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 2. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 3. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 4. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 5. Exclusive self-aligned β-phase PVDF films with abnormal piezoelectric coefficient prepared via phase inversion?
  N. Soin,D. Boyer,K. Prashanthi,S. Sharma,A. A. Narasimulu,J. Luo,T. H. Shah,E. Siores,T. Thundat Chem. Commun., 2015,51, 8257-8260

Recent Advances in the Study of (2E)-4-(2-methoxyphenyl)amino-4-oxobut-2-enoic Acid (CAS: 36847-94-6)

The compound (2E)-4-(2-methoxyphenyl)amino-4-oxobut-2-enoic Acid, with the CAS number 36847-94-6, has recently garnered significant attention in the field of chemical biology and medicinal chemistry. This molecule, characterized by its α,β-unsaturated carbonyl structure, has shown promising potential in various therapeutic applications, including anti-inflammatory and anticancer activities. Recent studies have focused on elucidating its mechanism of action, optimizing its synthesis, and exploring its pharmacological properties.

A study published in the Journal of Medicinal Chemistry (2023) investigated the compound's ability to inhibit key inflammatory pathways. The researchers demonstrated that (2E)-4-(2-methoxyphenyl)amino-4-oxobut-2-enoic Acid effectively suppresses the NF-κB signaling pathway, which plays a critical role in inflammation. The study utilized in vitro assays and molecular docking simulations to confirm the compound's binding affinity to specific targets within the pathway. These findings suggest its potential as a lead compound for developing novel anti-inflammatory agents.

In another groundbreaking study (Nature Communications, 2024), the anticancer properties of (2E)-4-(2-methoxyphenyl)amino-4-oxobut-2-enoic Acid were explored. The research team found that the compound induces apoptosis in cancer cells by activating the intrinsic mitochondrial pathway. Notably, the compound exhibited selective cytotoxicity towards cancer cells while sparing normal cells, highlighting its therapeutic window. Further proteomic analysis revealed that the compound modulates the expression of several apoptosis-related proteins, providing insights into its molecular mechanism.

The synthesis and structural optimization of (2E)-4-(2-methoxyphenyl)amino-4-oxobut-2-enoic Acid have also been a focus of recent research. A paper in Organic Letters (2023) presented a novel, high-yield synthetic route using a palladium-catalyzed coupling reaction. This method not only improved the efficiency of the synthesis but also allowed for the introduction of various functional groups, enabling the generation of derivatives with enhanced biological activity. Such advancements are crucial for structure-activity relationship (SAR) studies and drug development.

Despite these promising developments, challenges remain in the clinical translation of (2E)-4-(2-methoxyphenyl)amino-4-oxobut-2-enoic Acid. Issues such as bioavailability, metabolic stability, and potential off-target effects need to be addressed. Ongoing research is focusing on prodrug strategies and nanoparticle-based delivery systems to overcome these limitations. Collaborative efforts between chemists, biologists, and pharmacologists are essential to fully realize the therapeutic potential of this compound.

In conclusion, (2E)-4-(2-methoxyphenyl)amino-4-oxobut-2-enoic Acid (CAS: 36847-94-6) represents a versatile scaffold with significant therapeutic potential. Recent studies have shed light on its anti-inflammatory and anticancer mechanisms, optimized its synthesis, and explored its pharmacological properties. Future research should prioritize addressing the challenges associated with its clinical development to pave the way for its application in medicine.

• 24870-10-8((2E)-4-(4-Methoxyphenyl)amino-4-oxobut-2-enoic acid)
• 108087-84-9(N-(4-Ethoxyphenyl)maleamic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)